Comparative Pharmacology
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus MONOCID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus MONOCID.
KEFUROX IN PLASTIC CONTAINER vs MONOCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
1 g intramuscularly or intravenously every 24 hours; for severe infections, 2 g every 24 hours.
None Documented
None Documented
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Terminal elimination half-life: 4-5 hours (prolonged to 12-24 hours in severe renal impairment; dosing adjustment recommended for CrCl <50 mL/min).
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Renal: ~90% unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: ~5% (cefonicid undergoes minimal hepatic metabolism; ~4% excreted in feces as parent drug and metabolites).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic